Skip to main content
Adolescent Health, Medicine and Therapeutics logoLink to Adolescent Health, Medicine and Therapeutics
. 2022 Sep 25;13:77–91. doi: 10.2147/AHMT.S383872

Human Papillomavirus Vaccination Uptake and Its Predictors Among Female Adolescents in Gulu Municipality, Northern Uganda

Caroline Aruho 1, Samuel Mugambe 2, Joseph Baruch Baluku 3, Ivan Mugisha Taremwa 2,
PMCID: PMC9524482  PMID: 36186270

Abstract

Background

Human papillomavirus (HPV) is the putative case of cervical cancer. However, uptake of HPV vaccination is reportedly low in Uganda. This study explored the predictors of HPV vaccination uptake among female adolescents aged 15–18 years in Gulu Municipality, in northern Uganda.

Methods

This was an analytical cross-sectional survey that was conducted among adolescents aged 15–18 years in Gulu Municipality. A structured questionnaire was used. Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 25. Descriptive statistics and a log binomial model were used to analyze the factors associated with HPV vaccination uptake.

Results

Less than a quarter of the female adolescents (22%) aged 15–18 years in Gulu municipality, Gulu district, had been vaccinated with the human papillomavirus vaccine. HPV vaccination uptake was lower by 23% among adolescents who stayed with their mothers only (aPR = 0.769, CI = 0.595–0.995, P = 0.046), and by 14% among adolescents whose parents were unmarried (aPR 0.859, CI = 0.776–0.951, P=0.003).

Conclusion

This study reports a low HPV vaccination coverage among adolescents in Gulu Municipality, which is associated with parental perceptions and marital status. Efforts to increase uptake should focus on parents of adolescents.

Keywords: human papillomavirus, cervical cancer, vaccination uptake, Uganda

Background

More than 80% of sexually active men and women worldwide are at risk of contracting Human Papillomavirus (HPV).1 HPV is responsible for an estimated 630,000 new cases of cervical and genitourinary cancer worldwide each year.2 The prevalence of cervical cancer is steadily increasing in low-income countries and causes significant morbidity and mortality.3–6

HPV screening and vaccination is projected to prevent up to one death per 100,000 women by 2034.7 Furthermore, efforts have been directed toward promoting primary prevention through the vaccination of adolescents.8,9 Because HPV infection is transmitted sexually,10 the 3-dose quadrivalent recombinant HPV vaccination strategy targets female adolescents aged 9 to 14 years,11 for whom the first vaccination dose should be administered before a sexual encounter.12,13 Despite the global vaccination campaign to prevent HPV-related morbidity, HPV vaccination uptake remains unacceptably low.14,15 In Uganda, HPV vaccination was launched in 2015, and the 2-dose HPV vaccine series has since been integrated in the routine Uganda National Expanded Program on Immunization.11,16 Uganda has the 7th highest incidence of cervical cancer and cervical cancer-related mortality in the world but HPV vaccination uptake is low.16 For example, a study of 460 female adolescents in the Lira district in northern Uganda found that HPV vaccination uptake was 17.61%.17 More, research evidence from Eastern Uganda affirmed an HPV vaccination initiation coverage of 49%, with 13.8% receiving the second vaccination dose.18 The low HPV vaccination uptake is multifaceted and can be attributed in part to a variety of predictors such as low vaccine knowledge, fear of pain, vaccine side effects, ethnicity, age, sexual behavior, immunization history, and school attendance status.16–22 Besides, some parents’ beliefs that HPV vaccination might encourage promiscuity, earlier sexual debut in young girls, and that the vaccine might lead to unsafe sexual behavior were barriers to HPV vaccination uptake.22–26 According to the Uganda Demographic and Health Survey (2016), only 12% of the targeted population in Gulu Municipality had been vaccinated, and the figure rose by a meager 5% (to 17%) in 2018 (District Health Information Software2, 2018).27 Studies are needed to further characterize the paltry HPV vaccine uptake in this region. The current study investigated the predictors of HPV vaccination uptake among female adolescents aged 15–18 years in Gulu Municipality, northern Uganda, to better understand the determinants of HPV vaccination uptake.

Methods

Study Design, Site, and Duration

We conducted a community-based cross-sectional survey in Gulu Municipality, northern Uganda. Gulu Municipality is bounded on the west by Amuru district, on the north east by Lamwo district, on the east by Pader district, on the southeast by Lira district, on the south by Oyam district, and on the southwest by Nwoya district. The region is a post-conflict area that was ravaged by the Lord Resistance Army insurgency from 1987 to 2006. This study was conducted between July to December 2020.

Study Population and Enrolment

The population was dyadic, consisting of adolescents aged 15 to 18 years old and their parents. The 15–18 age group was chosen because the study was conducted in 2020, which corresponded to five years after the introduction of HPV vaccination. Thus, at the time of the official launch of the HPV vaccination campaign in 2015, this age group (10–15 years) was eligible for HPV vaccination. The study included female adolescents between the ages of 15 and 18 who were legitimate residents of Gulu Municipality, northern Uganda.

Sample Size Estimation and Sampling

The study used a formula by Nassiuma28 given by;

graphic file with name Tex001.gif

Where n is the estimated sample size, N is the population size (50,000 female adolescents in Gulu Municipality targeted in the district’s HPV vaccination program),27 C is the coefficient of variation (fixed between 0 and 30%), and e is the margin of error (fixed between 2–5%). On substitution with a 25% coefficient of variation, a 95% confidence interval, a 5% margin of error, and a population of 50,000;

graphic file with name Tex002.gif

Thus, a minimum of 250 female adolescents were considered.

Multi-stage sampling was used to select the participants. First, stratified sampling was used to stratify the four divisions of Gulu district, and each division was treated as a stratum from which parishes were later randomly sampled. This was accomplished by numbering all parishes in a given stratum and writing the numbers on separate pieces of paper. The papers with those numbers were ruffled and placed, one at a time, in a box until the required number was reached. The selected papers were unfolded, and the numbers inscribed on them were checked to ensure that they corresponded with the numbers on the previously created parish outline. The parishes with the same number as those sampled in a given division were chosen. The other three strata followed the same procedure. Thereafter, convenience sampling method was used in a village to sample the households. In this, a household in a given village was approached, rapport was established with the inhabitants, and an interview was conducted if eligible inhabitants (a parent and a 15-year-old female adolescent) were present. Following that, the nearest household in any direction was approached until the required number of households was obtained. This prerequisite number was based on the calculation;

graphic file with name Tex003.gif

Where; Nrp represented the number of adolescents and parents needed per parish; NP as the total number of eligible adolescents available in a sampled parish, which was estimated by the local government records (2019), and n being the estimated sample size (250). Thus,

Sub County NP NT n Nrp
Bardege 7619 32,506 250 59
Laroo 6331 32,506 250 49
Layibi 7977 32,506 250 61
Pece 10,579 32,506 250 81

Study Variables

The dependent variable was HPV vaccination, and the independent variables were institutional, parental, and adolescent-related predictors. The health services were the institutional predictors, whereas the parental predictors were the characteristics of the parents and/or guardians. Female adolescent characteristics that influenced HPV vaccination uptake were referred to as adolescent-related predictors. These variables were developed using theoretical modeling for health promotion research that is centered on tier three of promotion, in which contextual influences of health behavior are defined as those that allow for the integration of multiple levels of influence to establish an overall view of health behavior change. The triadic theory of influence (TTI)29 was used in this case. Following the TTI, three constructs were chosen as independent variables and conceptualized (Figure 1).

Figure 1.

Figure 1

The conceptual frame based on the triadic theory of influence relating the independent variables towards the uptake of HPV vaccination.

Data Collection Approach and Tool

A structured questionnaire (Appendix 1) was used to collect quantitative data, which was divided into five sections: sociodemographic characteristics, HPV vaccination status, assessment of institutional characteristics, assessment of parental characteristics, and adolescent-related characteristics. Based on existing literature, this was developed16,17,29–35 and pretested among 25 female adolescents in Kisenyi parish, Makindye division, Kampala City. Following that, changes were made to improve clarity, content, and comprehension. The adolescent’s role was to complete two sections of the questionnaire before her parent was interviewed privately. Before data collection, the expert review was used to ensure content validity through psychometric testing. In addition, survey research assistants were recruited and trained in tandem with the objectives, questionnaire, assenting, and consent processing. Following the acquisition of assent/consent, the adolescents were engaged first in the absence of their parents, and then their parents were asked to respond to questions in the other sections in the absence of the adolescents.

Data Management and Analysis

Questionnaires were compiled and reviewed for omissions, response errors, and missing responses daily. Those who were affected were corrected, and if multiple significant deviations were discovered, this inclusion was dropped and compensated for by enrolling an additional participant. Once all questionnaires were cleaned and deemed ready, they were entered into SPSS version 25.0. Descriptive analysis was carried out, tabulated, and reported as frequencies and percentages. Bivariate analysis was used to determine the relationships between variables. We performed bivariate analysis with the log-binomial model since the magnitude of the outcome was greater than 10%. From the bivariate analyses, significant variables (p<0.05) were still fitted into a log-binomial model, and co-founding characteristics were controlled for. The confounders were socio demographic and parental characteristics, which were chosen depending on the variable being adjusted. At this level, statistical significance was established using an alpha level of 5%, and findings were reported in terms of prevalence ratios at 95% confidence.

Ethical Approval and Participant Consent

This study was approved by the research and ethics committee of Clarke International University (UG-REC-0015). Also, administrative permission was obtained from the authorities in Gulu Municipality. All participants provided written assent and consent for those under, and above 18 years, respectively. Participation was entirely voluntary, and confidentiality was ensured.

Results

Characteristics of Participants

A total of 250 adolescent-guardian pairs participated in the study. 58.0% (N = 145) of these adolescents were 15 to 16 years old, and 78.0% (N = 195) were still in school. Furthermore, 82.4% (N=206) of the adolescents were under the care of both parents. In contrast, 90.4% (N= 226) of the guardians were female, with 65.2% (N=163) being their mothers to the adolescents. Table 1 shows the socio-demographic characteristics and the perception towards the HPV vaccine safety.

Table 1.

Showing Socio-Demographic Characteristics and Perceptions of the Adolescents-Parent/Guardian Pairs

Variable Category Frequency (n=250) Percentage
Adolescents socio-demographic characteristics
Age 15 to 16 years 145 58.0
17 to 18 years 105 42.0
Still in school Yes 195 78.0
No 55 22.0
School-level in Primary 24 12.3
Secondary 171 87.7
Religious affiliation Christian 204 81.6
Muslim 46 18.4
Tribe belonged to Acholi 207 82.8
Not Acholi 43 17.2
Parent/guardian socio-demographic characteristics
Gender Male 24 9.6
Female 226 90.4
Age 18 to 30 years 23 9.2
31 to 42 years 83 33.2
42 to 54 years 125 50.0
> 54 years 19 7.6
Educated Yes 231 92.4
No 19 7.6
School-level Primary 84 36.4
Secondary 132 57.1
Post-secondary 15 6.5
Relationship with the adolescent Father 44 17.6
Mother 163 65.2
Guardian 19 7.6
Auntie 3 1.2
Grandparent 21 8.4
Current marital status Married 170 68.0
Single 58 23.2
Separated 22 8.8
Perceptions of the HPV vaccination (Worry about the safety of vaccines like HPV)
Variable Yes = 182 No = 68 Total
The general view about childhood vaccination
It is important 147 (75.4%) 48 (24.6%) 195 (100.0%)
Not all vaccinations are important 32 (64.0%) 18 (36.0%) 50 (100.0%)
The vaccinations are too many 3 (60.0%) 2 (40.0%) 5 (100.0%)
Fear of side effects of vaccines
The general view about childhood vaccination
It is important 147 (75.4%) 48 (24.6%) 195 (100.0%)
Not all vaccinations are important 32 (64.0%) 18 (36.0%) 50 (100.0%)
The vaccinations are too many 3 (60.0%) 2 (40.0%) 5 (100.0%)

HPV Vaccination Uptake, Awareness and Intention to Vaccinate

Among all adolescents, 52.0% (N = 130) had never received HPV vaccination. Figure 2 shows that 22% (N=55) of those vaccinated had received two doses of the HPV vaccine. Moreover, 73.6% (N=184) of the adolescents were unaware of the availability of an HPV vaccine. 79.6% (N=199) of female parents/guardians had never been screened for cervical cancer, 69.6% (N=174) had never heard of HPV, and only 38.8% (N=97) thought HPV vaccination was safe for adolescent girls.

Figure 2.

Figure 2

The proportion of the HPV vaccinated, and their vaccination schedule.

Also, 82.8% (N=207) of parents/guardians had no plans to vaccinate their daughters against HPV before the age of 14. Furthermore, 72.8% (N=182) of the guardians who did not support HPV vaccination reportedly feared the vaccine’s side effects. Despite this, 64.4% (N=161) of guardians were aware that their daughters were at risk of cervical cancer if they were not immunized. More than 75.4% of guardians who said childhood vaccinations were important were concerned about vaccine safety against HPV, and an equal number were concerned about vaccine side effects.

Factors Associated with HPV Vaccination Uptake

The following parental characteristics were statistically significant with HPV vaccination: general opinion of childhood vaccination (p<0.001), parents staying with the child (p<0.001), and current marital status (p<0.001). According to the institutional characteristics, 60.0% (N=150) of the parents had never received advice about HPV vaccination for their daughter from a health worker. Moreover, only 54.4% (N=136) of girls had been educated about the importance of HPV vaccination. Only 55.6% (N=139) said they had never been informed about the availability of HPV vaccines at health facilities. Furthermore, 49.2% (N=123) of parents reported that their daughters’ schools did not provide HPV vaccination services. The institutional factors had no statistically significant relationship with HPV vaccination uptake.

Table 2 shows the bivariate analysis findings between, adolescent, parental characteristics and HIV vaccination. The parental characteristics of general view about childhood vaccination (p<0.001), staying with parents (p<0.001), and current marital status (p<0.001) showed a statistically significant association in multivariate analysis. The prevalence of HPV vaccination uptake was lower by 12% among adolescents whose parents thought childhood vaccination was important (aPR = 0.882, CI = 0.835–0.931, p< 0.001). Further HPV vaccination uptake was lower by 23% among adolescents who stayed with their mothers only (aPR = 0.769, CI = 0.595–0.995, P = 0.046), and by 14% among adolescents whose parents were unmarried (aPR 0.859, CI = 0.776–0.951, P=0.003), Table 3 summarizes these findings.

Table 2.

Showing an Unadjusted Relationship Analysis Between Adolescent and Parental Characteristics and HPV Vaccination

Variable n=250 % HPV Vaccination Status cPR (95% CI) P-value
Vaccinated (2 HPV Doses), N = 55 Vaccinated (Single or no HPV Doses), N = 195
Adolescent characteristics
Sexually active
 Yes 41 16.4 9 (22.0%) 32 (78.0%) 0.997 (0.531–1.875) 0.993
 No 209 83.6 46 (22.0%) 163 (78.0%) 1.000
Adolescents received all childhood vaccines
 Yes 209 83.6 45 (21.5%) 164 (78.5%) 0.883 (0.486–1.605) 0.683
 No 41 16.4 10 (24.4%) 31 (75.6%) 1.000
Aware of HPV
 Yes 58 23.2 11 (19.0%) 47 (81.0%) 0.828 (0.458–1.496) 0.531
 No 192 76.8 44 (22.9%) 148 (77.1%) 1.000
Aware of the existence of the HPV vaccine
 Yes 66 26.4 17 (25.8%) 49 (74.2%) 1.247 (0.758–2.052) 0.385
 No 184 73.6 38 (20.7%) 146 (79.3%) 1.000
Current age
 15 Years 108 43.2 20 (18.5%) 88 (81.5%) 0.920 (0.575–1.472) 0.728
 16 years 142 56.8 35 (24.6%) 107 (75.4%) 1.000
Still in school
 Yes 195 78.0 5 (20.8%) 19 (79.2%) 1.442 (0.754–2.758) 0.269
 No 55 22.0 46 (23.6%) 149 (76.4%) 1.000
School-level
 Primary 24 12.3 5 (20.8%) 19 (79.2%) 0.869 (0.381–1.981) 0.738
 Secondary 171 87.7 41 (24.0%) 130 (76.0%) 1.000
Religious affiliation
 Christian 204 81.6 45 (22.1%) 159 (77.9%) 1.015 (0.554–1.860) 0.962
 Muslim 46 18.4 10 (21.7%) 36 (78.3%) 1.000
Tribe belonged to
 Acholi 207 82.8 46 (22.2%) 161 (77.8%) 1.062 (0.563–2.002) 0.853
 Not Acholi 43 17.2 9 (20.9%) 34 (79.1%) 1.000
Parental characteristics
Heard about the HPV vaccination program
 Yes 174 69.6 35 (20.1%) 139 (79.9%) 1.036 (0.970–1.106) 0.297
 No 76 30.4 20 (26.3%) 56 (73.7%) 1.000
HPV vaccination is regarded as safe for adolescent girls
 Yes 97 38.8 20 (20.6%) 77 (79.4%) 1.013 (0.955–1.074) 0.672
 No 153 61.2 35 (22.9% 118 (77.1%) 1.000
The general view about childhood vaccination
It is important 195 78.0 44 (22.6%) 151 (77.4%) n.a
 Not all vaccinations are important 50 20.0 11 (22.0%) 39 (78.0%)
The vaccinations are too many 5 2.0 0 (0.0%) 5 (100.0%)
Had any intentions to vaccinate their daughter for HPV before she made 14 years
 Yes 43 17.2 9 (20.9%) 34 (79.1%) 1.007 (0.934–1.086) 0.850
 No 207 82.8 46 (22.2%) 161 (77.8%) 1.000
Heard about HPV
 Yes 76 30.4 19 (25.0%) 57 (75.0%) 0.976 (0.915–1.041) 0.463
 No 174 69.6 36 (20.7%) 138 (79.3%) 1.000
Ever screened for cervical cancer (Females)
 Yes 46 20.4 12 (26.1%) 34 (73.9%) 0.969 (0.895–1.050) 0.443
 No 180 79.6 37 (20.6%) 143 (79.4%) 1.000
Adolescent stays with both parents
 Yes 206 82.4 43 (20.9%) 163 (79.1%) 1.037 (0.955–1.126) 0.386
 No 44 17.6 12 (27.3%) 32 (72.7%) 1.000
Parents stayed with
Mother only 21 47.7 7 (33.3%) 14 (66.7%) n.a n.a
Father only 17 38.6 4 (23.5%) 13 (76.5%)
Relatives 5 11.4 1 (20.0%) 4 (80.0%)
Friends 1 2.3 0 (0.0%) 1 (100.0%)
Father involvement in daughter affairs
 Yes 62 24.8 13 (21.0%) 49 (79.0%) 0.955 (0.861 −1.059) 0.381
 No 172 68.8 40 (23.3%) 132 (76.7%) 0.943 (0.858 −1.035) 0.216
 Not sure 16 6.4 2 (12.5%) 14 (87.5%) 1.000
The extent of paternal involvement
 To a large extent 21 33.9 2 (9.5%) 19 (90.5%) 1.103 (0.934–1.302) 0.248
 To some extent 30 48.4 8 (26.7%) 22 (73.3%) 1.004 (0.840–1.199) 0.969
 To a small extent 11 17.7 3 (27.3%) 8 (72.7%) 1.000
Fear of side effects of vaccines
 Yes 182 72.8 41 (22.5%) 141 (77.5%) 0.989 (0.928–1.054) 0.738
 No 68 27.2 14 (20.6%) 54 (79.4%) 1.000
Worried about the safety of the HPV vaccine
 Yes 182 72.8 41 (22.5%) 141 (77.5%) 0.989 (0.928–1.054) 0.738
 No 68 27.2 14 (20.6%) 54 (79.4%) 1.000
Adolescents have ever been refused to be vaccinated, by parents or guardian
 Yes 38 15.2 9 (23.7%) 29 (76.3%) 1.092 (0.584–2.040) 0.784
 No 212 84.8 46 (21.7%) 166 (78.3%) 1.000
Daughter at risk of cervical cancer in case she does not get vaccinated
 Yes 161 64.4 36 (22.4%) 125 (77.6%) 0.994 (0.937–1.056) 0.852
 No 89 35.6 19 (21.3%) 70 (78.7%) 1.000
Kind of parenthood to the daughter
 Authoritarian 182 72.8 37 (20.3%) 145 (79.7%) 1.035 (0.967–1.109) 0.321
 Permissive 68 27.2 18 (26.5%) 50 (73.5%) 1.000
Daughter health decision-maker
One of the parents 140 56.0 39 (27.9%) 101 (72.1%) 0.984 (0.769–1.258) 0.896
Both parents 87 34.8 11 (12.6%) 76 (87.4% 1.071 (0.838–1.368) 0.586
The entire family 19 7.6 4 (21.1%) 15 (78.9%) 1.023 (0.786–1.330) 0.868
The adolescent herself 4 1.6 1 (25.0%) 3 (75.0%) 1.000
Gender
Male 24 9.6 5 (20.8%) 19 (79.2%) 1.007 (0.910–1.108) 0.882
Female 226 90.4 50 (22.1%) 176 (77.9%) 1.000
Age
18 to 30 years 23 9.2 2 (8.7%) 21 (91.3%) 0.330 (0.072–1.516) 0.154
31 to 42 years 83 33.2 18 (21.7%) 65 (78.3%) 0.824 (0.350–1.940) 0.658
42 to 54 years 125 50.0 30 (24.0%) 95 (76.0%) 0.912 (0.404–2.059) 0.825
More than 54 years 19 7.6 5 (26.3%) 14 (73.7%) 1.000
Receive any formal education
 Yes 231 92.4 51 (22.1%) 180 (77.9%) 0.994 (0.894–1.106) 0.916
 No 19 7.6 4 (21.1%) 15 (78.9%) 1.000
School-level
Primary 84 36.4 19 (22.6%) 65 (77.4%) 0.985 (0.871 −1.115) 0.816
Secondary 132 57.1 29 (22.0%) 103 (78.0%) 0.989 (0.878–1.114) 0.856
Post-secondary 15 6.5 3 (20.0%) 12 (80.0%) 1.000
Relationship with the adolescent
Father 24 9.6 11 (25.0%) 33 (75.0%) 1.050 (0.418–2.636) 0.917
Mother 183 73.2 34 (20.9%) 129 (79.1%) 0.876 (0.385 −1.992) 0.752
Guardian 19 7.6 4 (21.1%) 15 (78.9%) 0.884 (0.277–2.818) 0.835
Auntie 3 1.2 1 (33.3%) 2 (66.7%) 1.400 (0.238–8.250) 0.710
Grand parent 21 8.4 5 (23.8%) 16 (76.2%) 1.000
Current marital status
Married 170 68.0 33 (19.4%) 137 (80.6%) 0.946 (0.881–1.016) 0.125
Single 58 23.2 20 (34.5%) 38 (65.5%) 0.867 (0.787–0.955) 0.004*
Separated 22 8.8 2 (9.1%) 20 (90.9%) 1.000
Institutional characteristics
Received advice from any health workers about getting daughter vaccinated for HPV
 Yes 100 40.0 27 (27.0%) 73 (73.0%) 1.446 (0.909–2.301) 0.119
 No 150 60.0 28 (18.7%) 122 (81.3%) 1.000
Community sensitization about the need for HPV vaccination
 Yes 136 54.4 28 (20.6%) 108 (79.4%) 1.018 (0.960–1.079) 0.558
 No 114 45.6 27 (23.7%) 87 (76.3%) 1.000
Been made aware of the availability of the HPV vaccines at health facilities
 Yes 111 44.4 30 (27.0%) 81 (73.0%) 0.950 (0.896–1.008) 0.092
 No 139 55.6 25 (18.0%) 114 (82.0%) 1.000
Community provision of HPV vaccination services by HCWs
 Yes 46 18.4 9 (19.6%) 37 (80.4%) 1.017 (0.947–1.092) 0.647
 No 204 81.6 46 (22.5%) 158 (77.5%) 1.000
Provision of HPV vaccination services at daughter’s school, by any organization
 Yes 47 18.8 9 (19.1%) 38 (80.9%) 0.806 (0.398–1.634) 0.550
 No 123 49.2 27 (22.0%) 96 (78.0%) 0.924 (0.552–1.547) 0.764
 Not sure 80 32.0 19 (23.8%) 61 (76.3%) 1.000
Vaccination services are provided for free in this district
 Yes 192 76.8 44 (22.9%) 148 (77.1%) 1.054 (0.465–2.388) 0.899
 No 35 14.0 6 (17.1%) 29 (82.9%) 0.789 (0.272–2.285) 0.662
 Not sure 23 9.2 5 (21.7%) 18 (78.3%) 1.000
Cost of HPV in district
More than 10,000 21 8.4 4 (19.0%) 17 (81.0%) 1.027 (0.894–1.180) 0.707
Less than 10,000 131 52.4 29 (22.1%) 102 (77.9%) 1.009 (0.904–1.128) 0.867
 Its free 77 30.8 17 (22.1%) 60 (77.9%) 1.010 (0.899–1.134) 0.868
 Not sure 21 8.4 5 (23.8%) 16 (76.2%) 1.000

Notes: n.a: represents no inferential analysis done for that particular variable, because of having a null integer in its cross tabulation. Variables indicated with * showed a statistically significant association.

Table 3.

Showing Multivariate Logistic Regression of the Predictors of HPV Vaccination Uptake

Variable cPR (95% CI) P value aPR (95% CI) P value
Parent stayed with
Mother only 0.833 (0.738–0.940) 0.003* 0.769 (0.595–0.995) 0.046
Father only 0.882 (0.787–0.989) 0.032 0.801 (0.582–1.103) 0.174
Relatives 0.900 (0.741–1.094) 0.289 0.848 (0.612–1.174) 0.320
Friends 1.000
Current marital status
Married 0.946 (0.881–1.016) 0.125 0.941 (0.872–1.014) 0.112
Single 0.867 (0.787–0.955) 0.004* 0.859 (0.776–0.951) 0.003
Separated 1.000

Note: Variables indicated with * showed a statistically significant association.

Discussion

In response to the current health scourge of cervical cancer, the cervical cancer triple intervention program was launched, with an HPV vaccination target of 90%, a screening target of 70%, and a treatment target of 80%.37 However, as this study discovered, HPV vaccination coverage was low, with only 22% receiving the double dose. This finding is surprising, but it is consistent with previous reports. HPV vaccination coverage, for example, was reported to be 2.6% in Nigeria,38 17.61% in the entire Uganda,18 and 13.8% in Eastern Uganda.18 Only one study, by Isabirye et al, reported a 22% HPV vaccination coverage in Uganda;36 however, their study did not consider two doses as an indicator. These findings indicate a significant gap, but the effectiveness of the HPV vaccine in reducing infection risk and cervical cancer-related mortality is dependent on receiving its effective dose.39,40 As a result, low HPV vaccine uptake is undoubtedly a significant impediment to achieving cervical cancer eradication.19,35,41,42 Previous reports have consistently shown that most adolescents receive only a single dose of the HPV vaccine,43–45 which is consistent with the findings of our study. However, because this is a suboptimal dose, the population is still at high risk of HPV sequel.46,47

The adolescent-related predictors of HPV vaccination uptake differed from the triadic theory of influence hypotheses. This study found no statistically significant association between characteristics in the proximal tier of influence (individual characteristics). This finding is because the vaccination window is between the ages of 9 and 14 years, an age range in which an adolescent has no control over their own health decisions, instead of relying on their parents or guardians.48

The parental-related predictors of HPV vaccination are consistent with the triadic theory of influence, which holds that distal characteristics (interpersonal) can be used to predict health behavior. In contrast to other studies,23,25,38 the findings of this study revealed that the prevalence of HPV vaccination was lower by 23% among adolescents who only lived with their mothers. This discovery is related to single parenthood, specifically single motherhood. This is because of patriarchy and a lack of socioeconomic support.49

The institutional predictors of HPV vaccination uptake did not show statistical significance. This supports the finding that whether or not an adolescent is vaccinated is at the discretion of the parents.50 This finding suggests that outreach to parents using various behavioral communication change approaches is necessary to increase HPV vaccination uptake. However, the findings of this study differ from previous reports that found an association with specific health care service characteristics.31,36,51 The difference in the latter studies was attributed to a relatively higher engagement with the adolescents’ parents. This emphasizes the importance of parental involvement in HPV vaccination programs.

The findings of this study should be interpreted in light of the fact that the study only included female adolescents who had passed the screening eligibility window (9 to 14 years). This implies that the study did not include adolescents who might have sought vaccination shortly or sought a second dose six months after the interview. Also, as the HPV vaccination had been launched 5-years prior to the conception and conduct of this study, there may have been a recall bias. This may have influenced the participants’ responses for this study.

Conclusion

Only 22% of female adolescents in Gulu Municipality were immunized against HPV. Furthermore, neither individual nor institutional characteristics predicted HPV vaccination uptake; rather, parental characteristics demonstrated significant predictive power. The following variables demonstrated statistical significance: perception of childhood vaccination, nature of parent stayed with if not both, and marital status. As a result, there is an urgent need to supplement and/or modify current behavior change communication efforts to focus on demystifying the HPV vaccine to parents.

Acknowledgments

We are grateful to the study participants. We gratefully acknowledge the research assistants who supported the data collection.

Funding Statement

The authors of this work did not receive any funding.

Abbreviations

HPV, Human Papillomavirus; TTI, triadic theory of influence.

Data Sharing Statement

All relevant data are within the paper. The questionnaire used is included in Appendix 1.

Ethics Approval and Consent to Participate

Ethical approval was obtained from the research and ethics committee of Clarke International University (UG-REC-0015). Participation was entirely voluntary, and confidentiality was ensured where a copy of the proposal with a consent form was presented for approval before the beginning of the study. Also, written informed consent was obtained from all participants. The anonymity of participants was ensured at all stages of data collection and analysis.

Author Contributions

CA, SM, BBJ and IMT conceived the study idea, and participated in study design; data acquisition, analysis, interpretation; and manuscript drafting and revision. SA, SM, BBJ and IMT oversaw the research design, cross-checked data collection tools. All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors declare no conflict of interest in this work.

References

  • 1.Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24:S4–S15. doi: 10.1016/j.vaccine.2005.09.054 [DOI] [PubMed] [Google Scholar]
  • 2.de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. doi: 10.1002/ijc.30716 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Jedy-Agba E, Joko WY, Liu B, et al. Trends in cervical cancer incidence in sub-Saharan Africa. Br J Cancer. 2020;123(1):148–154. doi: 10.1038/s41416-020-0831-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ndejjo R, Mukama T, Musabyimana A, Musoke D. Uptake of cervical cancer screening and associated factors among women in rural Uganda: a cross sectional study. PLoS One. 2016;11(2):e0149696. doi: 10.1371/journal.pone.0149696 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Desta M, Getaneh T, Yeserah B, et al. Cervical cancer screening utilization and predictors among eligible women in Ethiopia: a systematic review and meta-analysis. PLoS One. 2021;16(11):e0259339. doi: 10.1371/journal.pone.0259339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Nakisige C, Schwartz M, Ndira AO. Cervical cancer screening and treatment in Uganda. Gynecol Oncol Rep. 2017;20:37–40. doi: 10.1016/j.gore.2017.01.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Baussano I, Bray F. Modelling cervical cancer elimination. Lancet Public Health. 2019;4(1):e2–e3. doi: 10.1016/S2468-2667(18)30189-0 [DOI] [PubMed] [Google Scholar]
  • 8.Abdullahi LH, Kagina BM, Ndze VN, Hussey GD, Wiysonge CS. Improving vaccination uptake among adolescents. Cochrane Database Syst Rev. 2020;1(1):CD011895. doi: 10.1002/14651858.CD011895.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations. PT. 2016;41(7):426–436. [PMC free article] [PubMed] [Google Scholar]
  • 10.Gavillon N, Vervaet H, Derniaux E, Terrosi P, Graesslin O, Quereux C. Papillomavirus humain (HPV): comment ai-je attrapé ça? [How did I contract human Papillomavirus (HPV)?]. Gynecol Obstet Fertil. 2010;38(3):199–204. doi: 10.1016/j.gyobfe.2010.01.003 [DOI] [PubMed] [Google Scholar]
  • 11.World Health Organization. Human papillomavirus vaccines. WHO Position Paper. 2017;92(19):241–268. [PubMed] [Google Scholar]
  • 12.Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218–226. doi: 10.1093/aje/kwf180 [DOI] [PubMed] [Google Scholar]
  • 13.Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002;109:96–98. doi: 10.1111/j.1471-0528.2002.01053.x [DOI] [PubMed] [Google Scholar]
  • 14.Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother. 2019;15(1):146–155. doi: 10.1080/21645515.2018.1512453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Attia AC, Wolf J, Núñez AE. On surmounting the barriers to HPV vaccination: we can do better. Ann Med. 2018;50(3):209–225. doi: 10.1080/07853890.2018.1426875 [DOI] [PubMed] [Google Scholar]
  • 16.Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. doi: 10.1016/S2214-109X(19)30482-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kisaakye E, Namakula J, Kihembo C, Kisakye A, Nsubuga P, Babirye JN. Level and factors associated with uptake of human papillomavirus infection vaccine among female adolescents in Lira District, Uganda. Pan Afr Med J. 2018;31:184. doi: 10.11604/pamj.2018.31.184.14801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nabirye J, Okwi LA, Nuwematsiko R, et al. Health system factors influencing uptake of Human Papillomavirus (HPV) vaccine among adolescent girls 9–15 years in Mbale District, Uganda. BMC Public Health. 2020;20(1):171. doi: 10.1186/s12889-020-8302-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wymann MN, Zographos AS, Altpeter E, Spicher VM, Low N, Mäusezahl-Feuz M. Human papillomavirus vaccine uptake in adolescence and adherence to cervical cancer screening in Switzerland: a national cross-sectional survey. Int J Public Health. 2018;63(1):105–114. doi: 10.1007/s00038-017-1050-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Morales-Campos DY, Flores BE, Donovan E, et al. A qualitative descriptive study of providers’ perspectives on human papillomavirus vaccine administration among Latino/a adolescents in South Texas clinics: barriers and facilitators. BMC Public Health. 2022;22(443). doi: 10.1186/s12889-022-12837-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mihretie GN, Liyeh TM, Ayele AD, et al. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study. Reprod Health. 2022;19:136. doi: 10.1186/s12978-022-01444-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rujumba J, Akugizibwe M, Basta NE, Banura C. Why don’t adolescent girls in a rural Uganda district initiate or complete routine 2-dose HPV vaccine series: perspectives of adolescent girls, their guardians, healthcare workers, community health workers and teachers. PLoS One. 2021;16(6):e0253735. doi: 10.1371/journal.pone.0253735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Birmingham WC, Macintosh JLB, Vaughn AA, Graff TC. Strength of belief: religious commitment, knowledge, and HPV vaccination adherence. Psychooncology. 2019;28:1227–1233. doi: 10.1002/pon.5071 [DOI] [PubMed] [Google Scholar]
  • 24.Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188–194. doi: 10.1097/00128360-200407000-00005 [DOI] [PubMed] [Google Scholar]
  • 25.Walhart T. Parents, adolescents, children and the human papillomavirus vaccine: a review. Int Nurs Rev. 2012;59:305–311. doi: 10.1111/j.1466-7657.2012.00991.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zimet GD, Rosberger Z, Fisher WA, Perez S, Stupiansky NW. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. Prev Med. 2013;57:414–418. doi: 10.1016/j.ypmed.2013.05.013 [DOI] [PubMed] [Google Scholar]
  • 27.Gulu Municipality. District Health Information Software2; 2018.
  • 28.Nassiuma DK. Survey Sampling: Theory and Methods. Nairobi: University Press; 2000. [Google Scholar]
  • 29.Flay BR, Petraitis J. The theory of triadic influence: a new theory of health behavior with implications for preventive interventions. In: Albrecht GS, editor. Advances in Medical Sociology: A Reconsideration of Models of Health Behavior Change. Greenwich, CT: JAI Press. Vol. 4; 1994:19–44. [Google Scholar]
  • 30.Hollins A, Wardell D, Fernandez ME, Markham C, Guilamo-Ramos V, Santa Maria D. Human papillomavirus vaccination status and parental endorsement intentions among undergraduate student nurses. Int J Environ Res Public Health. 2021;18(6):3232. doi: 10.3390/ijerph18063232 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Bernat DH, Gerend MA, Chevallier K, Zimmerman MA, Bauermeister JA. Characteristics associated with initiation of the human papillomavirus vaccine among a national sample of male and female young adults. J Adolesc Health. 2013;53(5):630–636. doi: 10.1016/j.jadohealth.2013.07.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Krakow M, Beavis A, Cosides O, Rositch AF. Characteristics of adolescents lacking provider-recommended human papillomavirus vaccination. J Adolesc Health. 2017;60(5):619–622. doi: 10.1016/j.jadohealth.2016.11.028 [DOI] [PubMed] [Google Scholar]
  • 33.Anuforo B, McGee-Avila JK, Toler L, et al. Disparities in HPV vaccine knowledge and adolescent HPV vaccine uptake by parental nativity among diverse multiethnic parents in New Jersey. BMC Public Health. 2022;22(1):195. doi: 10.1186/s12889-022-12573-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Robles C, Bruni L, Acera A, et al. Determinants of human papillomavirus vaccine uptake by adult women attending cervical cancer screening in 9 European countries. Am J Prev Med. 2021;60(4):478–487. doi: 10.1016/j.amepre.2020.08.032 [DOI] [PubMed] [Google Scholar]
  • 35.de Munter AC, Klooster TMST, van Lier A, Akkermans R, de Melker HE, Ruijs WLM. Determinants of HPV-vaccination uptake and subgroups with a lower uptake in the Netherlands. BMC Public Health. 2021;21(1):1848. doi: 10.1186/s12889-021-11897-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Isabirye A, Mbonye M, Asiimwe JB, Kwagala B. Factors associated with HPV vaccination uptake in Uganda: a multi-level analysis. BMC Womens Health. 2020;20(1):145. doi: 10.1186/s12905-020-01014-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.World Health Organization. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. World Health Organization; 2020. [Google Scholar]
  • 38.Oluwole EO, Idowu OM, Adejimi AA, Balogun MR, Osanyin GE. Knowledge, attitude and uptake of human papillomavirus vaccination among female undergraduates in Lagos State, Nigeria. J Family Med Prim Care. 2019;8(11):3627–3633. doi: 10.4103/jfmpc.jfmpc_520_19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Cheng L, Wang Y, Du J. Human papillomavirus vaccines: an updated review. Vaccines. 2020;8(3):391. doi: 10.3390/vaccines8030391 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Liu G, Mugo NR, Bayer C, et al. Impact of catch-up human papillomavirus vaccination on cervical cancer incidence in Kenya: a mathematical modeling evaluation of HPV vaccination strategies in the context of moderate HIV prevalence. mEClinicalMedicine. 2022;19(45):101306. doi: 10.1016/j.eclinm.2022.101306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Dilley SE, Peral S, Straughn JM Jr, Scarinci IC. The challenge of HPV vaccination uptake and opportunities for solutions: lessons learned from Alabama. Prev Med. 2018;113:124–131. doi: 10.1016/j.ypmed.2018.05.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Dorji T, Nopsopon T, Tamang ST, Pongpirul K. Human papillomavirus vaccination uptake in low-and middle-income countries: a meta-analysis. EClinicalMedicine. 2021;34:100836. doi: 10.1016/j.eclinm.2021.100836 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sankaranarayanan R, Joshi S, Muwonge R, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36:4783–4791. doi: 10.1016/j.vaccine.2018.02.087 [DOI] [PubMed] [Google Scholar]
  • 44.Brotherton JM, Budd A, Rompotis C, et al. Is one dose of human papillomavirus vaccine as effective as three? A national cohort analysis. Papillomavirus Res. 2019;8:100177. doi: 10.1016/j.pvr.2019.100177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Pal M, Bandyopadhyay S. Single-dose nonavalent HPV vaccine: need of the hour. Nepal J Epidemiol. 2020;10(2):871–873. doi: 10.3126/nje.v10i2.28962 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Castellino SM, Allen KE, Pleasant K, Keyes G, Poehling KA, Tooze JA. Suboptimal uptake of human papillomavirus (HPV) vaccine in survivors of childhood and adolescent and young adult (AYA) cancer. J Cancer Surviv. 2019;13(5):730–738. doi: 10.1007/s11764-019-00791-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Lin L, Parra MM, Sierra VY, et al. Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in 4–6-year-old girls: results to month 12 from a randomized trial. Pediatr Infect Dis J. 2018;37(4):e93–e102. doi: 10.1097/INF.0000000000001871 [DOI] [PubMed] [Google Scholar]
  • 48.Glenn BA, Nonzee NJ, Tieu L, Pedone B, Cowgill BO, Bastani R. Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood. Vaccine. 2021;39(25):3435–3444. doi: 10.1016/j.vaccine.2021.04.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Siu JY, Fung TKF, Leung LH. Barriers to receiving HPV vaccination among men in a Chinese community: a qualitative study in Hong Kong. Am J Mens Health. 2019;13(1):1557988319831912. doi: 10.1177/1557988319831912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rabiu KA, Alausa TG, Akinlusi FM, Davies NO, Shittu KA, Akinola OI. Parental acceptance of human papillomavirus vaccination for adolescent girls in Lagos, Nigeria. J Family Med Prim Care. 2020;9(6):2950–2957. doi: 10.4103/jfmpc.jfmpc_102_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Matsuno RK, Seay J, Porter B, Tannenbaum K, Warner S, Wells N. Factors associated with human papillomavirus vaccine initiation and compliance among U.S. military service members. Mil Med. 2022. doi: 10.1093/milmed/usab562 [DOI] [PubMed] [Google Scholar]

Articles from Adolescent Health, Medicine and Therapeutics are provided here courtesy of Dove Press

RESOURCES